Skip to main content

DOAC Eligible Subjects

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Haemonetics
HaemoneticsMA - Boston
1 program
TEG6s DOAC CartridgeN/A1 trial
Active Trials
NCT02798328Completed385Est. Sep 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HaemoneticsTEG6s DOAC Cartridge

Clinical Trials (1)

Total enrollment: 385 patients across 1 trials

NCT02798328HaemoneticsTEG6s DOAC Cartridge

Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Start: Aug 2016Est. completion: Sep 2017385 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.